These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20577942)

  • 1. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Microtubule Drugs.
    Florian S; Mitchison TJ
    Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
    Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
    Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
    Pabla N; Sparreboom A
    Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubulin-interacting agents. Epilogue.
    Fahy J; Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1297-301. PubMed ID: 11472269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
    Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
    Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
    Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
    Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A; Hadfield JA; Lawrence NJ; McGown AT
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubulin inhibitors: a patent survey.
    Nepali K; Ojha R; Sharma S; Bedi PM; Dhar KL
    Recent Pat Anticancer Drug Discov; 2014 May; 9(2):176-220. PubMed ID: 23746164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New microtubular agents in pediatric oncology.
    Seibel NL; Reaman GH
    Invest New Drugs; 1996; 14(1):49-54. PubMed ID: 8880393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.